Iovance Biotherapeutics

Iovance Biotherapeutics is a biotechnology company focused on innovating, developing, and commercializing novel cancer immunotherapies using tumor-infiltrating lymphocytes (TIL). Founded in 2007 and headquartered in San Carlos, California, Iovance developed Amtagvi, the first FDA-approved T-cell therapy for solid tumor cancers. The company operates state-of-the-art cell therapy manufacturing facilities in Philadelphia, advancing clinical-stage pipelines targeting melanoma, non-small cell lung cancer, and other solid tumors.